FDA Accepts NDA for TLX101-Px (Pixclara)
Filed with ASX · · 3 pages · English
Summary by 6ix AI
This acceptance represents a significant milestone for the company as it aims to address unmet medical needs in glioma characterization. The FDA has assigned a goal date for the review of this application, indicating the timeline for potential approval. The company has indicated that its financial guidance for the upcoming fiscal year does not include revenue from this product.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Telix Strengthens Board with Additional Director Appointments
- Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement
- Telix Appoints David Gill as Non-Executive Director
- Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
- Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
Later from Telix Pharmaceuticals
- Telix and Regeneron Announce Radiopharma Collaboration
- Regeneron and Telix Announce Strategic Radiopharma Collaboration
- Telix and Regeneron Announce Strategic Radiopharma Collaboration
- Telix Refinances Convertible Bonds
- Telix Investor Presentation April 2026
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals